Transcriptomic and metabolic profiling of Tolvaptan treated Autosomal dominant polycystic kidney disease (ADPKD) patient.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology（2022）
Abstract
Our data indicates a potential molecular mechanism of Tolvaptan treatment in regulating the integrity of tight junction and kidney cells, and provides novel therapeutic targets in in ADPKD.
MoreTranslated text
Key words
dominant polycystic kidney disease,tolvaptan,metabolic profiling,adpkd
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined